Quick Takeaways:
- Zoetis UK has received approval from the UK Veterinary Medicines Directorate (VMD) for Lenivia (izenivetmab injection), a monoclonal antibody therapy indicated for the alleviation of pain associated with osteoarthritis in dogs. The long-acting injectable therapy targets nerve growth factor (NGF), a key mediator of pain and inflammation, and is designed to provide pain relief for up to three months following a single injection.
- The approval is supported by more than a decade of research and development in veterinary monoclonal antibodies. In field studies, dogs treated with Lenivia demonstrated improved mobility and reduced osteoarthritis-related pain after a single dose. The therapy is intended for use as part of an individualized osteoarthritis management plan under veterinary supervision.
- Osteoarthritis remains one of the most common chronic joint diseases in dogs, affecting nearly 40% of dogs regardless of age or size and often impacting mobility, sleep, behavior, and overall quality of life. With Lenivia, Zoetis expands its canine pain management portfolio with a long-acting therapeutic option aimed at supporting sustained comfort and mobility in dogs suffering from osteoarthritis-associated pain.
Why It Matters?
Lenivia strengthens Zoetis’ lead in monoclonal antibody–based pain management for dogs by adding a longer-acting OA option to its portfolio.
Market-wise, a single injection providing up to three months of osteoarthritis pain relief should drive strong uptake among vets and owners managing chronic canine OA (which affects an estimated ~40% of dogs), deepen Zoetis’ share in the high-value OA segment alongside Librela, and reinforce its differentiation versus traditional NSAIDs and generic analgesics in the UK market.
Source: Zoetis
